IGHV mutational status has long been used by clinicians to predict how CLL will behave and when treatment may be needed. 2 ...

Please provide your email address to receive an email when new articles are posted on . Younger patients deemed MRD negative before transplant who received non-TBI regimens achieved 2-year EFS ...

CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...

Kasen Diggs uses his love of golf to battle leukemia. His family is being honored at the American Cancer Society Richmond ...

Patients with acute leukemia prioritize tiredness as the most important health dimension over cognition, differing from the general public's preferences. Informal caregivers report significant ...

By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...

She found love in a hopeless place. Finding love in today’s digital dating world is no east feat — especially if you’re going through a life- changing experience. This is what happened to a young ...

Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax ...